{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=3",
    "query": {
      "condition": "Cancer of the Ovary",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 2194,
    "total_pages": 220,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T11:25:46.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04106492",
      "title": "Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SQ3370",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shasqi, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2020-08-01",
      "completion_date": "2023-09-07",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Palo Alto, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04106492"
    },
    {
      "nct_id": "NCT01091259",
      "title": "Irinotecan and Bevacizumab for Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2010-03",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2015-11-24",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091259"
    },
    {
      "nct_id": "NCT04487405",
      "title": "A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adnexal Mass"
      ],
      "interventions": [
        {
          "name": "OVAnex",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Aspira Women's Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 721,
      "start_date": "2020-06-25",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 9,
      "location_summary": "Chandler, Arizona • Lake Worth, Florida • Columbus, Georgia + 5 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04487405"
    },
    {
      "nct_id": "NCT03348631",
      "title": "Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Endometrial Endometrioid Adenocarcinoma",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2019-05-01",
      "completion_date": "2027-02-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 581,
      "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03348631"
    },
    {
      "nct_id": "NCT05995860",
      "title": "Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vulvar Cancer",
        "Ovarian Cancer",
        "Uterine Cancer",
        "Vaginal Cancer"
      ],
      "interventions": [
        {
          "name": "Intervention group triads",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2023-06-14",
      "completion_date": "2025-01-23",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 2,
      "location_summary": "Carmel, Indiana • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05995860"
    },
    {
      "nct_id": "NCT00178802",
      "title": "Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Endometrial Neoplasms",
        "Cervix Neoplasms",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 24,
      "start_date": "1996-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2010-04-23",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00178802"
    },
    {
      "nct_id": "NCT00989651",
      "title": "Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Fallopian Tube Carcinosarcoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Neoplasm",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "Ovarian Brenner Tumor",
        "Ovarian Carcinoma",
        "Ovarian Carcinosarcoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Tumor",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Stage IIA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIA Ovarian Cancer AJCC V6 and v7",
        "Stage IIB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 431,
      "start_date": "2009-10-28",
      "completion_date": "2020-04-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Augusta, Georgia + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00989651"
    },
    {
      "nct_id": "NCT00003896",
      "title": "S9912 Combination Chemo in Stage III Ovarian Cancer,",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 68,
      "start_date": "1999-09",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 104,
      "location_summary": "Tucson, Arizona • Davis, California • Duarte, California + 66 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Livermore",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003896"
    },
    {
      "nct_id": "NCT05103683",
      "title": "First in Human Study of TORL-1-23 in Participants With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "TORL-1-23",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TORL Biotherapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2021-11-17",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 9,
      "location_summary": "Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05103683"
    },
    {
      "nct_id": "NCT01815294",
      "title": "A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Neoplasms, Ovarian",
        "Neoplasms, Breast",
        "Advanced or Refractory Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "DOXIL/CAELYX (doxorubicin) Treatment Sequence AB",
          "type": "DRUG"
        },
        {
          "name": "DOXIL/CAELYX (doxorubicin) Treatment Sequence BA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2013-05",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-10-09T11:25:46.454Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815294"
    }
  ]
}